Skip to main content

Table 4 IRR for BC in relation to the studied polymorphisms among postmenopausal women in the DCH cohort

From: Alcohol-related breast cancer in postmenopausal women – effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial

 

ncases (%)

ncontrol (%)

IRRa (95 % CI)

IRRb (95 % CI)

P-valuec

(n = 687)

(n = 687)

rs10519297

     

AA

170 (25)

174 (25)

1.00 (ref.)

1.00 (ref.)

 

AG

341 (50)

361 (53)

0.98 (0.76–1.27)

0.94 (0.72–1.23)

0.15

GG

176 (25)

152 (22)

1.23 (0.90–1.68)

1.25 (0.91–1.72)

 

AG + GG

511 (75)

513 (54)

1.05 (0.82–1.34)

1.03 (0.80–1.32)

0.83

rs749292

     

GG

216 (31)

203 (30)

1.00 (ref.)

1.00 (ref.)

 

AG

332 (48)

352 (51)

0.89 (0.69–1.14)

0.89 (0.69–1.16)

0.62

AA

139 (20)

132 (19)

0.97 (0.71–1.33)

0.99 (0.72–1.37)

 

AG + AA

471 (68)

484 (70)

0.91 (0.72–1.15)

0.92 (0.72–1.17)

0.50

rs1062033

     

CC

203 (30)

186 (27)

1.00 (ref.)

1.00 (ref.)

 

CG

333 (48)

354 (52)

0.85 (0.66–1.10)

0.85 (0.65–1.11)

0.46

GG

151 (22)

147 (21)

0.92 (0.67–1.25)

0.94 (0.68–1.28)

 

CG + GG

484 (70)

501 (73)

0.87 (0.68–1.11)

0.88 (0.68–1.12)

0.30

rs10046

     

AA

182 (27)

188 (28)

1.00 (ref.)

1.00 (ref.)

 

AG

346 (50)

353 (51)

1.02 (0.79–1.31)

0.97 (0.75–1.26)

0.52

GG

159 (23)

146 (21)

1.16 (0.85–1.57)

1.15 (0.84–1.57)

 

AG + GG

505 (73)

499 (72)

1.06 (0.84–1.34)

1.02 (0.80–1.31)

0.86

rs4646

     

CC

372 (54)

371 (54)

1.00 (ref.)

1.00 (ref.)

 

CA

265 (39)

262 (38)

1.00 (0.80–1.25)

0.97 (0.77–1.21)

0.95

AA

50 (7)

54 (8)

0.96 (0.63–1.45)

1.00 (0.65–1.53)

 

CA + AA

315 (46)

316 (46)

0.99 (0.81–1.22)

0.97 (0.78–1.20)

0.78

rs6493487

     

AA

407 (59)

430 (62)

1.00 (ref.)

1.00 (ref.)

 

GA

245 (36)

218 (32)

1.23 (0.98–1.55)

1.24 (0.98–1.58)

0.16

GG

35 (5)

39 (6)

0.96 (0.60–1.54)

0.88 (0.54–1.44)

 

GA + GG

280 (40)

257 (38)

1.19 (0.95–1.48)

1.18 (0.94–1.48)

0.16

rs2008691

     

AA

479 (70)

470 (68)

1.00 (ref.)

1.00 (ref.)

 

GA

179 (26)

198 (29)

0.88 (0.69–1.11)

0.88 (0.69–1.12)

0.25

GG

29 (4)

19 (3)

1.43 (0.80–2.57)

1.45 (0.80–2.64)

 

GA + GG

208 (30)

217 (32)

0.93 (0.74–1.17)

0.93 (0.74–1.18)

0.57

rs3751591

     

TT

479 (70)

498 (72)

1.00 (ref.)

1.00 (ref.)

 

TC

182 (26)

176 (26)

1.07 (0.84–1.36)

1.07 (0.83–1.37)

0.60

CC

26 (4)

13 (2)

2.13 (1.04–4.39)

2.12 (1.02–4.43)

0.04

TC + CC

208 (30)

189 (28)

1.13 (0.89–1.42)

1.13 (0.89–1.44)

0.31

CC vs. TT + TCd

26 (4)

13 (2)

2.09 (1.02–4.29)

2.09 (1.00–4.34)

0.05

rs2445762

     

TT

359 (52)

365 (53)

1.00 (ref.)

1.00 (ref.)

 

TC

278 (40)

276 (40)

1.02 (0.81–1.27)

1.04 (0.83–1.31)

0.74

CC

50 (8)

46 (7)

1.10 (0.72–1.69)

1.19 (0.76–1.85)

 

TC + CC

328 (48)

322 (47)

1.03 (0.83–1.27)

1.06 (0.85–1.32)

0.61

rs11070844

     

CC

552 (80)

556 (81)

1.00 (ref.)

1.00 (ref.)

 

TC

129 (19)

125 (18)

1.06 (0.801–1.39)

1.06 (0.80–1.40)

0.88

TT

6 (1)

6 (1)

1.01 (0.33–3.13)

0.86 (0.27–2.73)

 

TC + TT

135 (20)

131 (19)

1.06 (0.81–1.38)

1.05 (0.80–1.38)

0.73

  1. aCrude
  2. bAdjusted for parous/nulliparous, number of births, age at first birth, length of school education (low, medium, high), duration of HRT use (years), BMI (kg/m2) and alcohol intake (10 g/day)
  3. cP-value for trend
  4. dCC versus TT and TC
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us